Equities

Marksans Pharma Ltd

MARKSANS:NSI

Marksans Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)300.50
  • Today's Change11.50 / 3.98%
  • Shares traded6.81m
  • 1 Year change+116.65%
  • Beta1.3135
Data delayed at least 15 minutes, as of Nov 12 2024 10:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments7,0037,1513,467
Total Receivables, Net4,5914,1953,978
Total Inventory6,1794,8474,244
Prepaid expenses251198--
Other current assets, total599362322
Total current assets18,62516,75312,012
Property, plant & equipment, net6,8113,8693,423
Goodwill, net395385300
Intangibles, net648708586
Long term investments------
Note receivable - long term374326
Other long term assets29414616
Total assets26,81021,90416,401
LIABILITIES
Accounts payable2,6832,3062,001
Accrued expenses142104110
Notes payable/short-term debt291416413
Current portion long-term debt/capital leases250157281
Other current liabilities, total533427758
Total current liabilities3,8983,4103,562
Total long term debt1,900657414
Total debt2,4411,2291,108
Deferred income tax106154176
Minority interest209199207
Other liabilities, total463319
Total liabilities6,1594,4524,378
SHAREHOLDERS EQUITY
Common stock453453409
Additional paid-in capital5,0455,0451,732
Retained earnings (accumulated deficit)14,25411,0559,247
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total898898635
Total equity20,65117,45212,023
Total liabilities & shareholders' equity26,81021,90416,401
Total common shares outstanding453453409
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.